General

ABL Diagnostics sponsored the NTDD Symposium in Utrecht (NL) ABL Diagnostics sponsored the NTDD Symposium in Utrecht and presented the DeepChek® kit for Tuberculosis Genotyping & Drug Resistance through NGS sequencing 🧬. Our Sales representatives Vito Grasso and Joffrey BIGNOUNGA had the opportunity to meet the very kind Dutch TB community.

Set up of New Generation Sequencing (NGS) for the detection of Ganciclovir Resistance in the Molecular Biology Laboratory of the Hospital de Clínicas. We would like to thank our local representative in Uruguay Biko which is our local representative in Uruguay and Molecular Biology Laboratory of the Hospital de Clínicas for highlighting our CMV genotyping

ABL DIAGNOSTICS, key player in the diagnosis of infectious diseases by genotyping, presents its development plan to the financial community ABL DIAGNOSTICS (Euronext Paris, FR001400AHX6, ABLD) today presents its ABLDX 2027 medium-term development plan to the financial community. Formed from the end-August 2022 merger of ABL France into the listed entity without activity ETABLISSEMENTS FAUVET-GIREL

Atout Capital a conseillé ABL Diagnostics pour la fusion-absorption de l’activité diagnostic médical d’ABL France à hauteur de 28 m€ ABL DIAGNOSTICS développe, fabrique et commercialise des kits de tests de diagnostic par détection moléculaire et de tests de génotypage par séquençage d’ADN, ciblant des maladies infectieuses chroniques. ABL DIAGNOSTICS a ainsi développé des produits

ABL Diagnostics at the Federation of Infection Societies congress Discover the scientific publications from our Innovation team and get more information about new products & services including:  Publication #1 (Poster n°98) Whole Genome Sequencing of Human BK Polyomavirus Using Next-Generation Sequencing View Descamps Veronique1,  Morel Virginie1,  Olivia Ardizzoni,   Amira Doudou,  Chalom Sayada,  Sofiane Mohamed, and Brochot

Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA On September 1st 2022, Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merged into ABL Diagnostics SA (ABLD), a worldwide leading international company, listed on Euronext Paris compartment C (ISIN FR001400AHX6), offering innovative and proprietary molecular biology assays and end-to-end

WHO algorithm v2021-06 for Tuberculosis resistance now available! We are pleased to announce the immediate availability of the WHO Catalog of Mutations (version 2021-06) in BacterioChek-TB, intended to be used for Mycobacterium tuberculosis drug resistance assessement. ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574

This week we are proud to have two new Distribution Partners on our side : – ELTA 90 Medical Genetics in Georgia– Infotec in Paraguay Both agreements will cover all ABL’s Diagnostics line of products, including the DeepChek® Assays and Software. See all the current Distributors ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat

We are pleased to announce that we entered into an exclusive distribution agreement  of ABL’s Diagnostics line of products, including the DeepChek® Assays and software:– With Retina Pharmaceuticals in Ethiopia;– With Bionova in Bolivia ! ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email :